Cellular Biomedicine Group Appoints Michael A. Caligiuri, MD as Chair of External Advisory Board
June 20 2017 - 6:00AM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the
“Company”), a clinical-stage biopharmaceutical firm engaged in the
development of effective immunotherapies for cancer and stem cell
therapies for degenerative diseases, today announced the
establishment of an External Advisory Board and the appointment of
Michael A. Caligiuri, MD, as Chair of the External Advisory Board.
Dr. Caligiuri will bring together experts from diverse disciplines
to provide knowledge and insight to help CBMG fulfill its mission
and build a network for development opportunities.
“It is an honor to welcome Dr. Caligiuri,
internationally recognized for his contribution to cancer research
collaboration, to lead CBMG’s newly formed External Advisory
Board,” said Terry Belmont, Chairman of the Board for the Company.
“Through his work with researchers, patients, advocates and
government officials, and his active involvement with the American
Association for Cancer Research (AACR) for over 25 years, he is an
ambassador for the cancer research community. Dr. Caligiuri’s focus
on leukemia, lymphoma and immunology is a strategic addition to our
team for further clinical development of our immuno-oncology
platform and translating cancer research to patient care. We look
forward to benefitting from the expertise and broad industry
network of Dr. Caligiuri."
“I am pleased to be joining and chairing the
External Advisory Board of CBMG, a company with high potential,
innovative therapeutics, and a seasoned management team. I look
forward to contributing to their development of safe and
effective immunotherapies for various cancer indications,” said Dr.
Caligiuri.
About Michael A. Caligiuri,
MDDr. Caligiuri is currently the Director of The Ohio
State University Comprehensive Cancer Center and Chief Executive
Officer of Ohio State’s James Cancer Hospital and Solove Research
Institute, which are members of Oncology Research Information
Exchange Network (ORIEN). He is a holder of the John L. Marakas
Nationwide Insurance Enterprise Foundation Chair in Cancer
Research. He has been actively involved with the AACR since 1990,
was elected to the AACR board of directors (2013-2016), and was
elected to serve as its 2017-2018 President. He also is a
professor in the Department of Internal Medicine and in the
Department of Cancer Biology and Medical Genetics in Ohio State’s
College of Medicine. Dr. Caligiuri has designed and conducted many
clinical studies for leukemia and lymphoma patients and has more
than 400 original publications, abstracts and review articles on
immunology or leukemia. He also is an elected member of the
American Association for Clinical Investigation and the American
Association of Physicians, and he is an elected Fellow in the
American Association for the Advancement of Science. He previously
served as the president of the Association for American Cancer
Institutes (AACI) and president for The Society for Natural
Immunity. Previously Dr. Caligiuri served as chair for the
Institute of Medicine’s National Cancer Policy Forum and served as
a member of the board for the American Society of Hematology
After earning a medical degree from the Stanford
University School of Medicine Stanford, CA, Dr. Caligiuri completed
an internship and residency in Internal Medicine at Brigham
and Women's Hospital at Harvard Medical School Boston, MA. He then
completed his fellowship in Medical Oncology, bone marrow
transplantation and immunology, Dana-Farber Cancer Institute at
Harvard Medical School, Boston, MA.
About Cellular Biomedicine Group Cellular
Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell
therapies for the treatment of cancer and degenerative diseases. We
conduct immuno-oncology and stem cell clinical trials in China
using products from our integrated GMP laboratory. Our GMP
facilities in China, consisting of twelve independent cell
production lines, are designed and managed according to both China
and U.S. GMP standards. CBMG recently commenced two Phase I
human clinical trials in China using CAR-T to treat Refractory
Diffuse Large B-cell Lymphoma (DLBCL), a Phase I human clinical
trial to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic
Leukemia (ALL), as well as an ongoing Phase I trial in China for
AlloJoinTM (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived
Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis
(KOA). CBMG was recently awarded $2.29 million from the California
Institute for Regenerative Medicine (CIRM) to support pre-clinical
studies of AlloJoinTM for Knee Osteoarthritis in the United States.
The Company also recently announced a strategic partnership with GE
Healthcare Life Sciences China to establish a joint technology
laboratory to develop control processes for the manufacture of
CAR-T and stem cell therapies. To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements Statements in this
press release relating to plans, strategies, trends, specific
activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995, Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking information is inherently subject to risks and
uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include risks inherent in doing business, trends affecting the
global economy, including the devaluation of the RMB by China in
August 2015 and other risks detailed from time to time in CBMG’s
reports filed with the Securities and Exchange Commission,
quarterly reports on form 10-Q, current reports on form 8-K and
annual reports on form 10-K. Forward-looking statements may be
identified by terms such as "may," "will," "expects," "plans,"
"intends," "estimates," "potential," or "continue," or similar
terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are
reasonable, they cannot guarantee that future results, levels of
activity, performance or achievements will be obtained. CBMG does
not have any obligation to update these forward-looking statements
other than as required by law.
Contacts:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cellular Biomedicine (NASDAQ:CBMG)
Historical Stock Chart
From Apr 2023 to Apr 2024